Company Filing History:
Years Active: 2025
Title: Innovations of Andrés Miguel Olivares Morales in Neurological Medications
Introduction
Andrés Miguel Olivares Morales is a distinguished inventor based in Binningen, Switzerland. He is recognized for his significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds aimed at treating neurological disorders. With two patents to his name, he actively contributes to advancements in healthcare.
Latest Patents
Andrés holds two notable patents related to benzodiazepine derivatives designed as GABA A gamma 1 positive allosteric modulators. Both inventions provide novel heterocyclic compounds represented by the general formula (I) and their pharmaceutically acceptable salts. These compounds have potential applications as medicaments, especially in treating or preventing acute neurological disorders, chronic neurological disorders, and cognitive impairments. The patents detail not only the chemical compositions but also the processes for manufacturing these compounds and the pharmaceutical compositions containing them.
Career Highlights
Andrés is currently associated with Hoffmann-La Roche Inc., a leading global pharmaceutical company. His work contributes to extensive research focused on innovative treatments in neurology and enhances the existing therapeutic options available for patients. His expertise in the field has positioned him as a valuable asset in pharmaceutical development.
Collaborations
Andrés collaborates with esteemed colleagues, including Bjoern Bartels and Giuseppe Cecere. These partnerships facilitate the fusion of ideas and expertise, driving forward the research and development of breakthrough medications within the pharmaceutical industry.
Conclusion
Andrés Miguel Olivares Morales stands out as an influential inventor with a focus on enhancing the treatment landscape for neurological disorders. His significant contributions, through innovative patent filings, underscore his commitment to advancing medicinal chemistry and improving patient care.